The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1

Richard J. Jones(Johns Hopkins University), Robert Z. Orlowski(University of North Carolina at Chapel Hill)

Journal of Pharmacology and Experimental Therapeutics

July 3, 2013

10.1124/jpet.113.204958

Cited by 26

Related Papers

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

|Journal of Clinical Oncology|2015|2.2k

VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION

|Transplantation|1987|914

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

|Leukemia|2007|839

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

|Leukemia|2011|721

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

|Journal of Clinical Oncology|2007|645